Kratom Batch Release and Quarantine: What Happens Between Testing and Sale

August 31, 2026

Educational notice: This guide explains product-quality concepts and does not provide medical or legal advice. FDA states that kratom is not lawfully marketed in the United States as a drug product, dietary supplement or conventional-food additive. References to 21 CFR Part 111 are used to explain a rigorous quality-system framework where relevant; they do not imply that FDA has approved kratom or accepted its sale as a dietary supplement. Kiody serves adults 21 and older and does not sell concentrated 7-hydroxymitragynine (7-OH).

The short answer

Kratom batch release is the documented decision that a specific lot may leave controlled hold status and become available for distribution. It should occur only after an authorized reviewer confirms that the lot identity, manufacturing and packaging records, specifications, test results, deviations, labels, quantity reconciliation and legal-market checks are complete and acceptable.

A certificate of analysis is important, but a passing COA does not release a batch by itself. The report might belong to a different lot, cover only some specifications, reflect a supplier sample rather than the finished packaged product, contain an unresolved revision or omit a result needed for a particular jurisdiction. Even a technically sound laboratory report cannot prove that the correct label was applied, the correct product went into the package, the lot remained protected in storage or the batch record is complete.

Until the release decision is made, the product should remain unmistakably unavailable for sale. A strong system uses both physical and electronic controls: segregated or clearly marked inventory, restricted access, an inventory status that blocks allocation, and a record showing who changed the status, when, why and from which evidence.

The basic principle is:

Test the right lot, review the whole record, resolve exceptions and release only through an authorized, traceable decision.

Why batch release deserves its own explanation

Consumers usually see the finished pouch, capsule bottle, lot code and perhaps a COA link. They do not see the period between packaging and sale. That period matters because the evidence about a batch is assembled from different sources at different times.

One laboratory may report alkaloids. Another may report microbiology or elemental impurities. Packaging records may be completed after bulk-product testing. A label revision may occur while results are pending. A shipping restriction can change after production but before fulfillment. A discrepancy in capsule count or powder yield can require investigation even when chemistry results pass.

Batch release is the point at which those separate facts are evaluated together. It is less like reading one green “PASS” box and more like closing a controlled case file.

This distinction builds trust without relying on vague claims such as “lab tested,” “certified” or “premium quality.” A useful public explanation tells customers what evidence matters, what each document can establish and why unresolved information should keep a lot on hold.

The regulatory context—and an important limitation

21 CFR Part 111 contains the federal current good manufacturing practice requirements for dietary supplements. Under 21 CFR §111.123, quality-control operations include reviewing batch-production records, conducting required material reviews, deciding disposition, determining whether specifications are met, and approving and releasing—or rejecting—each finished batch for distribution. The section also identifies circumstances in which quality-control personnel must not release a batch.

FDA’s Small Entity Compliance Guide for Part 111 explains the rule in question-and-answer form, including specifications, representative sampling, quarantine, batch records, packaging controls, reserve samples and release decisions.

Kratom requires an explicit qualification. On its current FDA and Kratom page, FDA says kratom is not lawfully marketed as a drug product, dietary supplement or conventional-food additive. Following controls modeled on Part 111 does not turn an unlawful marketing category into an approved one, and a COA is not FDA authorization.

Why use the framework here? Because the separation of manufacturing, testing, review, quarantine and release provides a concrete vocabulary for evaluating product-quality systems. Kiody should present those concepts as quality literacy, not as a claim that FDA has certified kratom, certified Kiody or approved any individual batch.

State and local requirements can add another layer. Some jurisdictions regulate age, licensing, registration, labeling, product form, delivery or alkaloid thresholds. A lot that passes an internal specification may still be ineligible for a particular destination. “Released” therefore needs a defined scope: released as what product, under what label, into which sales channels and for which jurisdictions?

Key terms that should not be blurred together

Quarantine

Quarantine is controlled status. The material or product is identified and held so it cannot be used or distributed until an authorized decision is made. Quarantine is not a prediction that the batch will fail. Newly received material, work in process, finished goods awaiting results and rejected goods awaiting disposition can all be quarantined for different reasons.

Hold

“Hold” is a practical status term, but it should be defined in the written system. A routine testing hold, legal-review hold, investigation hold and rejected-product quarantine are not interchangeable. A useful status includes a reason code and prevents release through the same controls as quarantine.

Approved

Approved can refer to a component, packaging material, label, process step, test result or finished batch. The object of the approval must be clear. An approved label does not release a finished lot, and approved bulk powder does not automatically approve every package filled from it.

Released

Released means an authorized decision has changed the lot from controlled hold to a defined state in which it may be distributed. Release should be specific to the finished product and packaging configuration. If the organization uses staged releases, the record should state exactly what is permitted and what remains prohibited.

Rejected

Rejected means the material or product is unsuitable for the intended use or distribution decision. Under 21 CFR §111.370, rejected dietary supplements must be clearly identified, held and controlled under a quarantine system for appropriate disposition. Section 111.425 applies similar controls to packaged and labeled dietary supplements rejected for distribution.

Disposition

Disposition is the documented decision about what will happen next. Possible outcomes may include rejection and destruction, return to a supplier, authorized reprocessing, relabeling under control, further investigation or another defined outcome supported by procedures and law. “Put it aside” is not a disposition.

Deviation

A deviation is a departure from an approved instruction, expected condition, specification or procedure. A deviation is not automatically a failure, and documenting it is not the same as accepting it. The deviation must be evaluated for its effect on identity, purity, strength, composition, contamination controls, packaging, labeling and traceability.

Out-of-specification result

An out-of-specification, or OOS, result falls outside an established acceptance criterion. It should not be averaged away, replaced by a convenient retest or relabeled as “close enough.” The laboratory and manufacturing investigations should follow written procedures, preserve the original result and establish a scientifically sound basis for any conclusion.

Reprocessing and rework

These terms are often used inconsistently. Reprocessing generally means repeating or adding a manufacturing step to bring a batch into conformance under an approved decision. “Rework” may be used more broadly in industry, but it should not become a vague permission to manipulate a failed product. The procedure, authorization, additional testing and new release review should be clear.

Stock recovery and recall

Recovering product that has not left the firm’s control is different from recalling distributed product. The release timestamp and first distribution record help determine which situation exists. A lot that was accidentally made saleable online but never shipped presents a different scope from one already delivered to customers.

The batch-release pathway

A practical release pathway can be understood as a series of gates. The precise sequence varies by product and organization, but skipping a gate should require a documented, justified exception—not an informal shortcut.

Gate 1: Receipt and unique identification

Raw botanical material, capsule shells, closures, labels and received finished product need unique identifiers that connect them to the supplier, receipt date, status and later batch records. Similar trade names are not enough. A receiving identifier should distinguish two deliveries of the same named powder.

The first status is ordinarily quarantine, not automatic approval. Receiving staff should examine container condition, seals, transport damage, documentation and obvious mismatches. A shipment labeled with one supplier lot while its COA names another should stay on hold.

Gate 2: Component and packaging approval

Identity and other applicable specifications are assessed before components are used. Packaging and labels are also checked and released for use. This matters because a correct formula in an incorrect package can still create a defective finished product.

A component COA can support the review, but supplier qualification, identity verification and the exact scope of reliance need to be defined. A generic COA downloaded from a supplier website should not be attached to whichever shipment happens to be in the warehouse.

Gate 3: Controlled manufacturing and in-process checks

The master manufacturing record describes how the product is intended to be made. The batch production record shows what actually happened for one batch. Ingredient weights, equipment, operators, dates, times, yields and in-process checks should be recorded as performed.

For pure-leaf capsules, useful controls may include bulk-lot identity, capsule-shell identity, blend handling, fill-weight or net-content checks, capsule count, metal-detection or sieve records where used, and yield reconciliation. For powder pouches, controls may focus on bulk-lot identity, handling, net weight, package integrity, lot coding and label reconciliation.

Gate 4: Packaging, label and lot-code verification

Before release, the reviewer should confirm that the correct product went into the correct package with the approved label. The printed lot code must connect the customer-facing package to the internal batch and applicable laboratory records.

Label reconciliation asks what happened to labels issued to the line: how many were used, returned, destroyed or investigated as discrepancies. Line-clearance records help show that material from the previous product or label version was removed. The result is not merely an accounting exercise. It reduces mix-ups that a chemical COA cannot detect.

Gate 5: Representative sampling and testing

A result is only as relevant as the sample. The record should connect the laboratory sample to the lot, location, sampler, date, container or time point, seal and chain of custody. Composite samples can be useful, but compositing may conceal variation if the sampling design is weak.

The release reviewer should know:

which specifications were tested;
which were verified by other controls;
whether the method was appropriate for the matrix;
whether the laboratory report is final;
whether quality-control data were acceptable;
whether any result was repeated, amended or qualified;
whether the tested sample represents bulk material or the finished packaged lot; and
whether the reported units and denominators match the specification.

Gate 6: Specification comparison

“Pass” must mean the result was compared with a predefined acceptance criterion. It should not be added after seeing the result. The specification version, units, basis and rounding rule should be available to the reviewer.

This is especially important for alkaloid limits. A result in milligrams per gram does not directly answer a percentage-of-total-alkaloids requirement. A per-serving restriction also depends on the declared or actual serving quantity. Converting among those bases requires the underlying data and transparent calculations.

Results below a laboratory’s reporting limit are not necessarily zeros. “Not detected” means the analyte was not detected under the reported method and limit. Near-threshold results deserve attention to measurement uncertainty, sample representativeness, rounding and jurisdiction-specific wording. None of those considerations permits changing a valid result merely to create a pass.

Gate 7: Exception investigation

Every unresolved deviation, OOS result, unexplained yield, damaged pallet, temperature excursion, missing signature or code mismatch is a release blocker until a procedure-supported decision says otherwise.

Investigation should ask whether the issue is isolated or systemic, whether other lots are implicated, whether original data remain trustworthy and whether corrective action is needed. An investigation that begins with “prove the batch can ship” has the wrong objective. The objective is to determine what happened and whether the evidence supports a defensible disposition.

Gate 8: Full batch-record review

The release reviewer checks the assembled record, not only the final page. A sensible review includes:

the current approved master record and formula;
unique component and packaging identifiers;
actual quantities and calculations;
equipment and line identification;
cleaning or line-clearance references;
production, packaging and holding dates;
in-process measurements;
actual and expected yields;
label issue and reconciliation;
finished-product inspection;
laboratory results and report status;
deviations, investigations and corrective actions;
reprocessing or relabeling authorization, if any;
reserve-sample confirmation;
remaining unresolved tasks; and
signatures or secure electronic approvals.

A missing field is not automatically critical, but it should not be silently ignored. The reviewer should determine what the field was intended to control, whether objective evidence can reconstruct it, and whether the gap affects confidence in the batch.

Gate 9: Market and legal-eligibility review

Product quality and market eligibility overlap but are not identical. A finished botanical powder might meet its internal contaminant and composition specifications while remaining ineligible for sale in a jurisdiction that prohibits delivery, requires product registration or applies a different 7-OH threshold.

The release record should therefore name the intended market scope. One practical design is to separate “quality release” from “commerce eligibility.” The first answers whether the batch meets the defined quality and packaging requirements. The second maps the approved product and label to current destinations and channels.

That separation prevents two mistakes: treating a local sales ban as if it proved the product failed laboratory testing, and treating a passing laboratory result as permission to ship everywhere.

Gate 10: Authorized disposition and status change

The final reviewer approves and releases or rejects the finished batch. The record should include the reviewer, decision, date and time, applicable product and lot, scope of release, supporting record version and any conditions.

The physical status, warehouse status, ecommerce allocation status and fulfillment status should change together or through a controlled sequence. If the quality system says “quarantine” but the ecommerce system says “in stock,” the customer-facing system can bypass the intended control.

Why a COA is necessary but not sufficient

A COA is a report of specified tests on a specified sample. It can provide strong evidence when the report is authentic, the method and laboratory are suitable, the sample is representative and the identifiers match. It cannot independently establish every release condition.

Consider what a COA generally cannot prove by itself:

that the sample was collected from the lot printed on the package;
that the entire lot was homogeneous;
that the report is the final, unrevised version;
that the correct powder or capsules entered each package;
that net weight or capsule count is correct;
that the correct label and warnings were applied;
that storage conditions remained acceptable after sampling;
that no contamination occurred after treatment or testing;
that all deviations were investigated;
that the lot is registered or saleable in every jurisdiction; or
that the product has been approved by FDA.

A public COA library improves transparency, but publication is separate from internal release. The lot should not become saleable merely because someone uploaded a PDF. Conversely, a temporary website-link error should not silently change the internal quality status of a previously released lot. The systems should be connected through documented checks without confusing one control for another.

Supplier COA, bulk COA and finished-product COA

These reports answer different questions.

Supplier COA

A supplier COA describes the supplier’s sample and lot. It can support incoming review, but it does not show what happened during later handling, blending, encapsulation, packaging or storage. The receiving firm must verify that identifiers match and determine what independent testing and supplier qualification are appropriate.

Bulk-product COA

A bulk COA describes material before final packaging. It may be highly relevant when packaging does not change composition, but it still does not establish package identity, correct labeling, net quantity, closure integrity or absence of a later mix-up.

Finished-product COA

A finished-product COA describes a sample taken from the completed product stage. Its strength depends on the sampling plan and the tests included. Even a comprehensive finished-product panel remains one portion of the release record.

Kiody’s product pages and central COA library should label the sample stage accurately. “Lot-specific lab results” is more useful than an unqualified “certified” badge. If one bulk lot supplies several package sizes, the public record can explain that relationship without pretending each size received a separate full analysis when it did not.

Physical and electronic quarantine should agree

A paper “HOLD” tag is fragile if units remain pickable in the inventory system. An electronic hold is fragile if unmarked pallets can be moved into an approved area. Strong control uses both.

Physical controls

Depending on scale and risk, these can include:

a segregated cage, room, rack or clearly bounded location;
conspicuous status labels with lot and reason;
tamper-evident seals or controlled pallet wrap;
restricted keys or access permissions;
separate areas for routine hold and rejected material;
controls against commingling partial containers; and
routine inventory checks.

Electronic controls

Useful features include:

lot-level status rather than SKU-only status;
allocation and pick blocking;
role-based permission to release;
reason codes;
required attachments or checklist completion;
audit history for every status change;
prevention of negative or manual inventory workarounds; and
synchronization with ecommerce and fulfillment systems.

A small company does not need a complex enterprise platform to apply the principle. A controlled spreadsheet plus locked physical location can be better than a sophisticated system with shared passwords and unrestricted overrides. The essential properties are clear status, traceability, authorization and effective prevention of unintended use.

Release authority should be protected from sales pressure

The person or function making the release decision needs enough independence to keep a batch on hold when evidence is incomplete. That does not require hostility between quality and operations. It requires defined roles.

Warning signs include:

a sales deadline determining when a lot “passes”;
warehouse staff releasing inventory because a customer is waiting;
the same person creating, executing, correcting and approving every record without review;
retrospective signatures after distribution;
management directing the laboratory to omit an inconvenient result;
inventory becoming saleable automatically when any PDF is uploaded; or
“conditional release” with no written definition or distribution block.

Quality review should be timely, but speed comes from prepared records, reliable laboratories and clear procedures—not from lowering the decision standard.

Partial and conditional release

Partial release may be legitimate in a carefully designed system, but it creates traceability risk. Examples include releasing one package configuration while another awaits label correction, or releasing a subset of physically identified units that was not exposed to a packaging deviation.

The record must define the released quantity, exact unit or pallet identifiers, product configuration, destination scope and evidence that the released portion is distinguishable. “Release half the batch” is not sufficient when no control identifies which half.

Conditional release is more dangerous when it means “ship now and finish paperwork later.” A condition that still allows affected product to reach a customer is not an effective quarantine condition. If an organization uses the term, it should define what is actually allowed—for example, moving sealed inventory from an external warehouse to an internal quarantine location—while continuing to block commercial distribution.

Testing pending after shipment is not a normal release control. If the result is required for the decision, the lot remains on hold until the final report and review are complete.

Product-specific release considerations

Pure botanical leaf powder

For leaf powder, release review may focus on botanical identity controls, supplier and origin documentation, microbial and elemental-impurity results, applicable pesticide or mycotoxin panels, alkaloid profile, lot homogeneity, net weight, pouch or jar integrity, label accuracy and the link from bulk lot to packaged lot.

Color or trade name should not substitute for identity. “Red,” “green,” “white,” “Bali” or “Maeng Da” are commercial descriptors, not self-authenticating quality specifications. The release record should use the actual internal product and lot identifiers.

Approximately 500 mg pure-leaf capsules

Kiody describes its ordinary capsules as containing approximately 500 mg of pure botanical leaf per capsule. Release evidence should distinguish that net fill from the gross capsule weight, which includes the shell. Relevant review may include shell material, count, fill-weight controls, blend or bulk-lot linkage, packaging inspection, label statements and finished-lot COA mapping.

A powder COA may support capsules made solely from the same qualified powder lot, but the relationship should be documented. The report does not establish capsule count, individual fill variation, shell identity or correct bottle labeling.

Extracts and enhanced products

Extracts require clarity about concentration, carrier, serving quantity, formulation calculations and units. A marketing ratio such as “10x” does not provide the same information as measured alkaloid content. Enhanced products need controls that identify every added ingredient and distinguish natural botanical variability from intentional fortification.

Kiody does not sell concentrated 7-OH. The release framework should not be used to suggest that a laboratory pass can override a prohibition, scheduling action or product-category restriction.

Liquids and gummies

These formats add formulation, mixing, unit-dose, water-activity, preservative, packaging and serving-size considerations. A powder-based result cannot automatically be carried over to a finished liquid or gummy without a defensible connection to the formulation and process.

Current federal 7-OH and derivative status

As of the draft date, two federal actions must be kept separate.

First, the proposed federal threshold action for 7-hydroxymitragynine is still a proposal. HHS extended the related information-request comment deadline to September 10, 2026 in its August 26, 2026 Federal Register notice. A proposed threshold should not be written into a release specification as if it were already the effective nationwide rule.

Second, DEA’s separate temporary order placing mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I is effective. The order took effect August 26, 2026 and states that it remains effective until August 26, 2028 unless extended or made permanent through further action. It applies federal Schedule I controls to handling the three named substances and covered forms described in the order.

A release review should therefore use current legal sources and exact analyte names. “Kratom alkaloids pass” is not enough to determine whether a scheduled derivative is involved. Ordinary botanical leaf, concentrated or enhanced 7-OH, synthesized or semisynthesized products, and the three scheduled derivatives are not interchangeable categories.

What happens when something does not match

Mismatch management is one of the best tests of a quality system. The easy batches do not reveal whether controls work under pressure.

Lot mismatch

If the COA names lot A26-041 and the packages show A26-014, keep the product on hold. Do not assume a typographical error. Confirm the source data, sampling record, laboratory accession and packaging record. If a corrected report is issued, preserve the original and the reason for amendment.

Product-name mismatch

Trade names may change, but the internal material identity must remain traceable. A report for “Green Powder” should not be assigned to “Premium White” merely because both appear green to the eye. Establish the documented relationship or obtain appropriate evidence.

Quantity mismatch

An unexplained yield can signal a recording error, spill, overfill, underfill, mix-up or unrecorded transfer. Reconcile actual output, samples, rejects, waste and retained material. A good chemical result does not close a material-balance discrepancy.

Label mismatch

If the correct lot was packaged under the wrong label, the product stays on hold. Controlled relabeling may be evaluated when lawful and technically appropriate, but the original error, affected quantity, label reconciliation and reinspection should be documented.

Test-result mismatch

If one report passes and another fails, the failed result remains part of the record. Investigate sampling, method, preparation, instrument performance and product variation. Selecting the favorable report without a scientifically sound investigation is not batch release.

Legal-status mismatch

If the product meets internal specifications but is ineligible for a destination, restrict that destination. Do not rewrite a quality pass as a legal pass. Preserve the batch’s quality status while enforcing the current commerce rule in the shipping matrix.

Five worked release reviews

Scenario 1: Passing bulk COA, missing package-lot link

A pure-leaf powder bulk lot has passing alkaloid, microbiology and elemental-impurity reports. Finished pouches are complete, but the packaging record does not show which of two bulk containers fed the line. Both containers have similar trade names.

Decision: Keep the packaged lot on hold. The reports may be valid, but representativeness and lot identity have not been established for the finished units. Review material issue records, weights, timestamps, container identifiers and line documentation. Release only if objective evidence reconstructs the connection under an approved investigation.

Scenario 2: Capsule lot passes chemistry, count discrepancy remains

Pure-leaf capsules made from a qualified powder lot have acceptable chemistry results. The batch should have produced 1,000 bottles of 100 capsules, but reconciliation shows an unexplained difference equivalent to several bottles.

Decision: Do not release merely because the COA passes. Investigate issued bulk quantity, fill weight, samples, rejects, damaged bottles, line clearance and recorded waste. The discrepancy could reflect documentation error or a packaging-control problem. Close it before disposition.

Scenario 3: Near-threshold 7-OH result with wrong denominator

An extract report lists 7-OH in milligrams per gram. A sales employee converts the number to a percentage using package net weight and declares that it meets a jurisdiction’s percentage-of-total-alkaloids limit.

Decision: Keep the lot out of that market. Package weight is not total alkaloid content. Obtain the data and calculation required by the actual rule, confirm serving information and method reporting, and have the result reviewed against the jurisdiction’s exact language. Do not infer compliance from an invalid denominator.

Scenario 4: Correct product, obsolete label

The powder lot and testing are acceptable, but the line used an old label that lacks a currently required statement for the intended market. Product has not shipped.

Decision: Quarantine the finished units. Evaluate controlled relabeling or repackaging, reconcile all old and replacement labels, reinspect a representative sample and complete a new release review. This is a stock-recovery and correction problem while the product remains under control, not yet a customer recall.

Scenario 5: Quality release completed, local delivery ban identified

A botanical leaf lot meets its internal specifications and the batch record is complete. Before orders ship, the law tracker confirms that a city prohibits delivery of covered kratom products.

Decision: Preserve the quality release but block sales and shipment to that jurisdiction. Document the source, effective date and operational scope in the commerce-eligibility matrix. Do not describe the lot as chemically failed or destroy product solely because one destination is prohibited.

Twenty warning signs in a release system

Finished goods appear online before the final release signature.
Any employee can change a lot from hold to saleable.
The inventory system tracks only SKU, not lot.
Physical pallets have no visible status.
A COA is assigned based on product color or trade name.
Supplier reports lack matching lot identifiers.
Amended laboratory reports replace originals without history.
“Not detected” is rewritten as zero.
Near-threshold values are rounded before the rule and method are checked.
A specification is created after the result is known.
Missing signatures are added after distribution with no explanation.
Deviations are closed as “operator error” without evidence or corrective action.
Failed results disappear after retesting.
Labels are not reconciled.
Yield discrepancies are ignored when chemistry passes.
Bulk results are presented as finished-package tests without explanation.
A local sales restriction is treated as a nationwide product failure.
A quality release is treated as permission to ship everywhere.
Rejected goods remain beside approved inventory without effective control.
“Conditional release” means customer shipment before required evidence is complete.

A proposed 40-field kratom batch-release record

This is a suggested review structure, not a claim that every field is legally required for every product or that Kiody currently uses this exact form.

Product and lot identity

Internal product name
Customer-facing product name
Product form
Finished lot or batch number
Related bulk lot number
Package size or capsule count
SKU or UPC
Manufacturing date
Packaging date
Intended market and sales channel

Manufacturing and packaging review

Master-record version
Batch-record identifier
Component-lot list reviewed
Packaging-lot list reviewed
Equipment and line records complete
In-process checks complete
Actual yield
Expected yield and acceptable range
Yield discrepancy disposition
Label version and reconciliation result
Finished-package inspection result
Lot-code legibility and accuracy check
Reserve sample identifier and location

Laboratory and specification review

Laboratory name and report number
Sample stage: component, bulk or finished package
Sampling-record reference
Chain-of-custody reference
Specification version
Required test panel
Final report status and revision number
Method or scope qualifications reviewed
Units, denominator and calculations checked
Each required result accepted, rejected or not applicable
OOS, atypical or near-threshold review reference

Exceptions, law and disposition

Deviation and investigation list
Reprocessing or relabeling authorization
State and local commerce-eligibility review date
Federal 7-OH and derivative-status review date
Final disposition, scope, reviewer and timestamp
Physical, inventory, ecommerce and fulfillment status verification

Frequently asked questions

1. What does “batch released” mean on a kratom quality record?

It means an authorized reviewer made a documented decision that a defined finished lot could leave hold status for a defined distribution scope. It should not mean merely that testing started or that one result passed.

2. Is a passing COA the same as a batch release?

No. The COA is evidence about a sample and listed tests. Release also requires review of identity, specifications, records, packaging, labeling, deviations, holding conditions and applicable market restrictions.

3. Does quarantine mean the kratom failed?

No. Routine quarantine prevents use or sale while required review is incomplete. A new shipment or finished lot awaiting results may be quarantined without any known defect.

4. Can a quarantined lot be listed as “in stock”?

The quantity may exist physically, but it should not be customer-available or allocable. Public inventory should reflect the effective release control, not merely the number of units in the building.

5. Who should release a batch?

The organization’s written procedure should identify authorized quality-control personnel or a defined reviewing function with appropriate training and independence. Warehouse or sales urgency should not substitute for authorization.

6. Can the laboratory release the lot?

A laboratory can approve and issue its report under its own controls. Unless the laboratory is also assigned the manufacturer’s complete release function and has all required records, it cannot evaluate packaging, labeling, deviations, legal-market scope and the rest of the finished-batch file.

7. What if the COA has the wrong lot number?

Keep the product on hold. Confirm whether the error is in the sample record, laboratory accession, report transcription or product record. An amended report should preserve traceability to the original and explain the correction.

8. Can a supplier COA release finished Kiody packages?

Not by itself. It can support incoming-material review when the lot matches and reliance is justified. Finished-package release still needs the downstream production, packaging, labeling, specification and exception review.

9. Is every batch required to receive every possible test?

The testing plan depends on the applicable requirements, specifications, risks, supplier controls, statistical plan and product. Part 111 allows certain finished-batch verification approaches, but the basis must be documented and quality-control reviewed. Public claims should accurately state what the particular lot was tested for.

10. What is a material review?

It is a documented evaluation of a deviation or specification failure to determine the effect on the batch and decide disposition. It may examine causes, related lots, reprocessing, corrective action and whether the product must be rejected.

11. Can a failed lot be blended with a passing lot?

Blending to conceal or dilute a failure is not a legitimate release shortcut. Any proposed processing must be lawful, procedurally authorized, scientifically justified, traceable and followed by the required testing and release review. Some failures require rejection.

12. What happens to rejected kratom?

It should be clearly identified and controlled under quarantine pending documented disposition. Depending on the facts and lawful options, disposition might involve destruction, return or an authorized corrective process. It should not quietly reenter saleable stock.

13. Can part of a lot be released?

Only if the released portion is objectively identified, independently supported by the record and controlled so held units cannot be shipped. Partial release should not be used when the affected and unaffected units cannot be distinguished.

14. Does release prove the product is safe for everyone?

No. Release means the batch met a defined review standard; it is not a medical guarantee. Individual risks, interactions and legal restrictions are outside what a batch-release record can prove.

15. Does release mean FDA approved the product?

No. FDA says kratom is not lawfully marketed as a drug, dietary supplement or conventional-food additive. A private release decision, COA or quality-system claim is not FDA approval or certification.

16. How should botanical leaf be distinguished from concentrated 7-OH?

The product identity, ingredients, formulation and alkaloid results should make the category clear. Ordinary pure leaf should not be described as a concentrated 7-OH product, and concentrated, enhanced, synthesized or semisynthesized products should not be presented as ordinary leaf.

17. Are mitragynine pseudoindoxyl, MGM-15 and MGM-16 covered by the pending 7-OH proposal?

They are subject to a separate effective DEA temporary scheduling order. The three named substances entered Schedule I on August 26, 2026. The threshold proceeding for 7-OH is distinct and remained proposed on this draft date.

18. What should a shopper look for?

Look for a legible lot number, accurate product form and net quantity, complete ingredient and business information, a lot-matched COA with clear sample and test details, and explanations that do not overstate what testing proves. Be cautious when a seller substitutes badges or medical promises for traceable records.